by Madaline Spencer | May 1, 2025
Nicola Longo, MD, PhD, Professor and Chief of Division of Clinical Genetics at the University of California, Los Angeles, discusses data presented at the 2025 ACMG Annual Clinical Genetics Meeting highlighting the benefits of sepiapterin in patients with classical...
by Madaline Spencer | Apr 30, 2025
The U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel or pz-cel) for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (EB). EB is a group of rare genetic skin diseases that cause the skin to...
by Madaline Spencer | Apr 29, 2025
The U.S. Food and Drug Administration (FDA) has approved nivolumab plus ipilimumab for first-line therapy in adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). HCC is a rare carcinoma of the liver characterized by nodules occurring anywhere...
by Madaline Spencer | Apr 24, 2025
A new study published in American Journal of Hematology compared two treatment options for Graft versus host disease (GVHD). Graft Versus Host Disease GVHD is a rare complication that can occur after a stem cell or bone marrow transplant. It is caused by the newly...
by Madaline Spencer | Apr 23, 2025
Sindhu Ramchandren, MD, Executive Medical Director, Neuroscience and Disease Cluster Lead for Neuroimmunology and Neuromuscular Disorders at Johnson & Johnson, discusses updated results from the Vivacity-MG3 clinical trial in patients with generalized myasthenia...
